← Back to Search

Cholinesterase Inhibitor

Pyridostigmine for Postural Tachycardia Syndrome

Phase 2
Recruiting
Led By Phillip A. Low, M.D.
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial will compare the effects of pyridostigmine to placebo in treating postural tachycardia syndrome. The researchers expect that pyridostigmine will improve tachycardia and stabilize blood pressure.

Who is the study for?
This trial is for individuals with Postural Tachycardia Syndrome (POTS), characterized by a rapid increase in heartbeat upon standing. Participants must experience symptoms like weakness, dizziness, blurry vision, nausea, heart palpitations, and concentration issues. Pregnant or breastfeeding women, those with thyroid disorders, significant heart disease or other illnesses affecting the autonomic system are excluded.
What is being tested?
The study tests pyridostigmine against a placebo over three days to see if it can reduce the fast heartbeat and stabilize blood pressure in POTS patients. The goal is to determine whether pyridostigmine is effective in treating symptoms of POTS compared to an inactive substance.
What are the potential side effects?
While not specified here, common side effects of pyridostigmine may include stomach cramps, diarrhea, increased saliva and urine production, muscle twitching and sweating. Placebo typically has no active ingredients but can cause perceived side effects due to patient expectations.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: pyridostigmineActive Control1 Intervention
Active study drug
Group II: PlaceboPlacebo Group1 Intervention
Control

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,360 Previous Clinical Trials
3,065,891 Total Patients Enrolled
4 Trials studying Postural Orthostatic Tachycardia Syndrome
103 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,384 Previous Clinical Trials
652,638 Total Patients Enrolled
4 Trials studying Postural Orthostatic Tachycardia Syndrome
359 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
National Institutes of Health (NIH)NIH
2,840 Previous Clinical Trials
8,172,068 Total Patients Enrolled
7 Trials studying Postural Orthostatic Tachycardia Syndrome
544 Patients Enrolled for Postural Orthostatic Tachycardia Syndrome
Phillip A. Low, M.D.Principal InvestigatorMayo Clinic

Media Library

Pyridostigmine (Cholinesterase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00409435 — Phase 2
Postural Orthostatic Tachycardia Syndrome Research Study Groups: Placebo, pyridostigmine
Postural Orthostatic Tachycardia Syndrome Clinical Trial 2023: Pyridostigmine Highlights & Side Effects. Trial Name: NCT00409435 — Phase 2
Pyridostigmine (Cholinesterase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00409435 — Phase 2
~0 spots leftby Feb 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top